Events & Presentations

Date	Event Details	Remind Me
Nov 30, 2021	Piper Sandler 33rd Annual Healthcare Conference View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation Listen to webcast
Dec 2, 2021 1:00 PM EST	4th Annual Evercore ISI HealthCONx Conference View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation Listen to webcast	Add to Outlook Add to Google Calendar
Dec 3, 2021	18th Global Cardiovascular Clinical Trialists Forum View Additional Information James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”	Add to Outlook Add to Google Calendar

Date	Event Details
Nov 13 - Nov 17, 2020	American Heart Association (AHA) Scientific Sessions 2020 Supporting Materials: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with dyslipidemia 348.4 KB Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia 679 KB Safety, Tolerability, and Efficacy of Single-dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a) 325 KB View Additional Information Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia Authors: Gerald F. Watts, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a) Authors: Michael J. Koren, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD
Nov 13 - Nov 16, 2020	The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Supporting Materials: ARO-AAT reduces serum and intra-hepatic Z-AAT protein in PiZZ alpha-1 antitrypsin deficient patients with liver disease leading to improvements in clinically relevant liver biomarkers 943.8 KB View Additional Information Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers Authors: Pavel Strnad, et al. Publication Number: LP14 Session: Late-breaking Abstract Posters
Oct 8, 2020 8:30 AM EDT	Arrowhead/Takeda Collaboration Call Listen to webcast Supporting Materials: Prepared Remarks 164.7 KB
Oct 6, 2020 1:30 PM EDT	Chardan Virtual 4th Annual Genetic Medicines Conference Register for webcast View Additional Information Vince Anzalone, CFA, Arrowhead’s vice president and head of investor relations, will participate in a fireside chat presentation
Sep 15, 2020 2:00 PM EDT	Cantor Fitzgerald Global Healthcare Conference 2020 Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 15, 2020 9:30 AM EDT	H.C. Wainwright 22nd Annual Global Investment Conference Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 10, 2020 2:00 PM EDT	Baird's 2020 Global Healthcare Conference Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 9, 2020	Citi’s 15th Annual BioPharma Virtual Conference
Aug 29 - Sep 1, 2020	European Society of Cardiology (ESC) Congress 2020 Supporting Materials: ESC 2020 ARO-APOC3 645.8 KB ESC 2020 ARO-ANG3 828 KB View Additional Information Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency Authors: Christian Schwabe, et al. Presenter: Christie M. Ballantyne Date and Time: August 31, 2020 at 10:50 CEST Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia Authors: Gerald F. Watts, et al. Date and Time: August 31, 2020 at 11:00 CEST
Aug 27 - Aug 29, 2020	The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) Supporting Materials: View Presentation 716.9 KB View Additional Information Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Authors: Edward Gane, et al.